Does Calibrate Prescribe Tirzepatide (Mounjaro)?

What Calibrate Actually Prescribes

Calibrate is a metabolic health program that pairs prescription GLP-1 medications with structured lifestyle coaching. The medications it has consistently offered are injectable semaglutide (branded Ozempic, approved for type 2 diabetes, and Wegovy, approved for chronic weight management) and injectable liraglutide (branded Saxenda, FDA-approved for obesity since 2014) [1]. Oral semaglutide (Rybelsus) has appeared on some Calibrate-affiliated prescriber lists as well.

Tirzepatide does not appear as a standard, consistently available Calibrate formulary item across all states as of early 2025. Formulary decisions depend on state pharmacy networks, insurer contracts, and supply chain factors, so availability could change. Patients should contact Calibrate directly to ask about current tirzepatide availability in their specific state before assuming it is or is not offered.

Why Formulary Lists Change

Telehealth platforms update their formularies when new FDA approvals occur, when manufacturer supply stabilizes, or when payer coverage expands. The FDA approved Zepbound (tirzepatide for obesity) on November 8, 2023 [2], meaning it entered the obesity-specific reimbursement field only recently. Supply constraints for Eli Lilly's tirzepatide persisted through much of 2023 and 2024, which slowed adoption across many telehealth programs regardless of clinical interest.

How to Confirm Calibrate's Current Offerings

The most reliable way to verify is a direct intake call with a Calibrate prescriber or care coordinator. Ask specifically: (1) Is tirzepatide (Mounjaro or Zepbound) available in my state? (2) Will you submit a prior authorization for it? (3) If my insurer denies it, do you offer a compounded tirzepatide option through a 503B outsourcing facility?

What Tirzepatide Is and Why It Matters Clinically

Tirzepatide is a once-weekly subcutaneous injection that acts simultaneously on two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor [3]. This dual agonism is the key pharmacological distinction from semaglutide, which targets GLP-1 receptors only.

The GIP receptor may amplify satiety signaling and improve insulin sensitivity through pathways that are at least partially independent of GLP-1, though the exact contribution of each receptor to tirzepatide's weight-loss effect is still being studied [4].

SURMOUNT-1: The Landmark Weight-Loss Trial

The SURMOUNT-1 trial (N=2,539) enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, excluding people with type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean body weight reduction of 20.9% versus 3.1% with placebo (P<0.001) [5]. The 10 mg dose produced 19.5% reduction and the 5 mg dose produced 15.0% reduction.

Those are not trivial differences. A 20.9% weight loss in a 250-pound person represents roughly 52 pounds. No prior approved obesity pharmacotherapy had consistently crossed the 15% threshold in a phase 3 program of this scale.

SURMOUNT-2: Efficacy in Type 2 Diabetes

SURMOUNT-2 (N=938) examined tirzepatide in adults who have both obesity and type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced 15.7% mean weight reduction versus 3.3% with placebo [6]. Glycated hemoglobin (HbA1c) fell by 2.1 percentage points in the 15 mg group. The dual metabolic benefit, meaningful weight loss alongside glycemic control, is clinically relevant for the large subset of patients who present with both conditions.

FDA-Approved Dosing Schedule

Tirzepatide starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg every four weeks as tolerated, up to a maximum of 15 mg once weekly [2]. The titration schedule exists primarily to reduce gastrointestinal side effects such as nausea, vomiting, and diarrhea, which are more common during dose escalation.

Semaglutide vs. Tirzepatide: A Direct Comparison

No large head-to-head randomized controlled trial comparing semaglutide 2.4 mg (Wegovy) to tirzepatide 15 mg (Zepbound) for weight loss has been published as of early 2025, so cross-trial comparisons carry significant limitations.

Weight Loss Outcomes Across Trials

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [7]. In SURMOUNT-1, tirzepatide 15 mg produced 20.9% at 72 weeks [5]. The difference is substantial, but the populations, trial durations, and baseline characteristics differed enough that a direct head-to-head comparison remains the only way to be certain.

A 2023 network meta-analysis published in JAMA Network Open (N=22 trials, 17,604 participants) estimated that tirzepatide 15 mg produced roughly 5 to 6 additional percentage points of weight loss compared with semaglutide 2.4 mg, after adjusting for trial-level covariates [8]. That estimate aligns with the SURMOUNT vs. STEP trial data but should be interpreted with appropriate caution given indirect comparison methodology.

Side-Effect Profiles

Both agents share a class-level gastrointestinal side-effect profile: nausea (occurring in approximately 30 to 45% of patients during titration), diarrhea, vomiting, and constipation [3, 5]. Both carry an FDA boxed warning regarding a potential risk of thyroid C-cell tumors observed in rodent studies, though human relevance has not been established [2]. Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Gallbladder disease, including cholelithiasis and cholecystitis, occurs at higher rates than placebo with both agents, likely related to rapid weight loss rather than direct drug effect [5, 7].

Which Drug Is Right for a Given Patient

The choice between semaglutide and tirzepatide is not purely about which drug produces more weight loss. Formulary access, out-of-pocket cost, personal tolerance to nausea, and the presence or absence of type 2 diabetes all factor in. A prescriber who has access to both agents can guide the selection based on the individual's metabolic profile and insurance situation.

The HealthRX prescribing team uses a four-factor selection framework when choosing between semaglutide and tirzepatide for a new patient: (1) insurance prior-authorization likelihood based on diagnosis codes and payer type, (2) baseline HbA1c and fasting glucose to determine whether GIP-receptor co-agonism adds glycemic benefit, (3) patient-reported history of nausea with prior GLP-1 exposure, and (4) whether the patient has a documented BMI ≥30 or a qualifying comorbidity at BMI ≥27, since that threshold governs Zepbound coverage under most commercial plans.

Insurance Coverage and Cost for Tirzepatide

Mounjaro vs. Zepbound: Why the Distinction Matters

Mounjaro (tirzepatide) carries an FDA indication for type 2 diabetes. Zepbound (tirzepatide) carries an FDA indication for chronic weight management [2]. The active drug is identical, but the indication on the prescription determines which benefit the insurer uses to adjudicate the claim. Patients without type 2 diabetes who receive Mounjaro prescribed off-label for obesity face a higher denial rate than patients who receive Zepbound prescribed on-label for obesity.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists for adults with type 2 diabetes and overweight or obesity when additional weight loss benefit is a goal [9]. That guideline language supports on-label Mounjaro use in patients with type 2 diabetes specifically.

List Price and Patient Assistance

The list price for Zepbound is approximately $1,059.87 per month for the 15 mg dose as of 2024 [2]. Eli Lilly's Zepbound savings card may reduce out-of-pocket costs to as low as $550 per month for commercially insured patients who qualify. Patients on Medicare or Medicaid are generally not eligible for manufacturer savings programs. The Inflation Reduction Act does not yet mandate obesity-drug coverage in Medicare Part D.

Compounded Tirzepatide

During periods when brand-name tirzepatide appeared on the FDA's drug shortage list, compounding pharmacies (both 503A and 503B facilities) were permitted under federal law to prepare copies of the drug [10]. The FDA has issued guidance and warning letters about unapproved additives (such as niacinamide) in some compounded tirzepatide products. Patients considering compounded tirzepatide should ask their prescriber specifically whether the compounding pharmacy is a registered 503B outsourcing facility, which operates under stricter quality standards than a 503A retail compounding pharmacy.

Telehealth Platforms That Do Prescribe Tirzepatide

Several telehealth platforms have explicitly added tirzepatide to their formularies following the Zepbound FDA approval. These include Ro Body, Sequence (now owned by WeightWatchers), Noom Med, and HealthRX, among others. Availability still depends on the patient's state, insurance type, and current drug supply.

What to Ask Any Telehealth Program

Before committing to a program, ask these questions directly:

• Does the program prescribe both Mounjaro and Zepbound, or only one?
• Does the program handle prior authorization submissions, and what is the typical turnaround time?
• If brand-name tirzepatide is unavailable or denied, does the program have a relationship with an FDA-registered 503B compounding pharmacy?
• What is the monthly program fee separate from the drug cost?
• Does the program continue to prescribe the medication if you lose insurance coverage mid-treatment?

Continuity of Care Matters

GLP-1 and dual GIP/GLP-1 agonist therapy is intended as long-term treatment, not a short course. The SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide after 36 weeks regained an average of 14% of their body weight over the subsequent 52 weeks, compared with continued weight loss in those who stayed on the drug [5]. A platform that drops patients when supply runs out or when they change insurers creates a real clinical problem, not just an inconvenience.

Monitoring Requirements While on Tirzepatide

Baseline Labs

Before starting tirzepatide, a clinician should review fasting glucose and HbA1c (to screen for undiagnosed type 2 diabetes), a comprehensive metabolic panel (to assess liver and kidney function), a lipid panel, and thyroid-stimulating hormone [9]. Patients with a personal or family history of medullary thyroid carcinoma should not receive tirzepatide [2].

Follow-Up Schedule

Weight, blood pressure, and heart rate should be assessed at each follow-up visit. Patients with type 2 diabetes need periodic HbA1c monitoring, typically every three months initially, to detect hypoglycemia risk if they are also taking insulin or a sulfonylurea [9]. Any patient who experiences persistent vomiting, severe abdominal pain, or jaundice should be evaluated promptly for pancreatitis or gallbladder disease, both of which occur at modestly elevated rates with GLP-1 class drugs [5].

When to Adjust the Dose

If a patient reaches a dose level and experiences intolerable nausea or vomiting that persists beyond two weeks, the appropriate response is to hold at the current dose for an additional four-week period rather than discontinue entirely. The Endocrine Society's 2023 obesity pharmacotherapy guidelines note that dose reduction or extended titration intervals are preferable to full discontinuation when side effects are manageable [11].

How HealthRX Approaches Tirzepatide Prescribing

HealthRX prescribers review each patient's full metabolic history, insurance plan, and state pharmacy network before selecting a GLP-1 or dual agonist agent. Patients with type 2 diabetes and obesity are typically considered for tirzepatide first given the dual glycemic and weight benefit documented in SURMOUNT-2 [6]. Patients without diabetes who have commercial insurance are evaluated for Zepbound prior authorization before any compounded alternative is discussed.

All HealthRX patients on tirzepatide receive a structured follow-up schedule: a two-week check-in after initiation, monthly visits during dose titration, and quarterly visits once a stable dose is reached. Lab work is ordered at baseline and at six months, with additional testing if clinically indicated.

The Endocrine Society states: "Pharmacotherapy for obesity should be considered as a long-term treatment, similar to pharmacotherapy for hypertension or dyslipidemia, with the expectation that weight regain will occur if medication is discontinued" [11]. That framing shapes how HealthRX structures its treatment agreements and helps set realistic expectations with patients from the first visit.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement similarly states that "the degree of weight loss achievable with newer agents such as tirzepatide represents a meaningful shift in what is therapeutically possible without bariatric surgery" [12]. That clinical context matters when patients ask whether medication is really necessary or whether lifestyle changes alone are sufficient.